InsidersTradesSigma
Track the Entero Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 8 January 2025 (Cession). Among the most active insiders: Romano Sarah. Every trade is accessible without an account.
Analysts rate Entero Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Entero Therapeutics, Inc. es una empresa biofarmacéutica enfocada en el desarrollo de tratamientos innovadores para trastornos gastrointestinales. Cotiza en el NASDAQ bajo el símbolo ENTR.